The EPS projection of ResMed Inc. (NYSE:RMD) for quarter ended 2016-09-30 is $0.67. Last week, the projection for EPS was $0.67 against target of $0.67, a month earlier. While 2-months ago, this projection was $0.67 versus forecast of $0.67a quarter months earlier, posting a deviation of 0%.
ResMed Inc. (NYSE:RMD) posted that 18 days earlier, the share price was revised 2 times on upside. In addition, negative revisions were 2.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 2, and 1, correspondingly.
The per-share earnings downgrade for ResMed Inc. (NYSE:RMD) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 0, and 1, in that order.
ResMed Inc. (NYSE:RMD) EPS target was $0.67 for the quarter closed 3. It was based on 5 calls. As on 2016-04-26 the EPS was $0.68. The change was $-0.01, posting a deviation of -1.45%. The price projections gave a standard deviation of 0.01.
Quarterly Sales Estimates
ResMed Inc. (NYSE:RMD) sales prediction for the fiscal 2017 stands at $547.283 and the median estimate is at $546.65. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $550.2 while the lowest target is $545 showing standard deviation of 2.657%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of 6.392%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...